Equity Overview
Price & Market Data
Price: $1.02
Daily Change: -$0.0099 / 0.97%
Daily Range: $1.01 - $1.05
Market Cap: $102,007,600
Daily Volume: 30,501
Performance Metrics
1 Week: -2.78%
1 Month: 2.94%
3 Months: -2.78%
6 Months: -23.36%
1 Year: -22.79%
YTD: -17.97%
Company Details
Employees: 22
Sector: Health technology
Industry: Biotechnology
Country:
Details
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.